デフォルト表紙
市場調査レポート
商品コード
1212645

腎臓がん治療薬の世界市場 2023

Kidney Cancer Drugs

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 148 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
腎臓がん治療薬の世界市場 2023
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 148 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

腎臓がん治療薬の世界市場は2030年までに81億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に56億米ドルと推定される腎臓がん治療薬の世界市場は、2022年から2030年にかけてCAGR 4.8%で成長し、2030年には81億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである標的療法は、CAGR5.1%を記録し、分析期間終了時には56億米ドルに達すると予測されます。パンデミック後の回復を考慮し、免疫療法分野の成長は、今後8年間のCAGRが4.2%に修正されました。

米国市場は15億米ドル、中国はCAGR8.2%で成長すると予測されています。

米国の腎臓がん治療薬市場は、2022年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが8.2%となり、2030年には17億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ2.5%と4%の成長が予測されています。欧州では、ドイツがCAGR3.2%で成長すると予測されています。

調査対象企業の例

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6797

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Kidney Cancer Drugs Market to Reach $8.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Kidney Cancer Drugs estimated at US$5.6 Billion in the year 2022, is projected to reach a revised size of US$8.1 Billion by 2030, growing at aCAGR of 4.8% over the period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 5.1% CAGR and reach US$5.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunotherapy segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 8.2% CAGR

The Kidney Cancer Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Select Competitors (Total 12 Featured):

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Kidney Cancer Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Angiogenesis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for mTOR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 21: World 18-Year Perspective for Cytokine Immunotherapy (IL-2) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 22: World Kidney Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 25: USA 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 28: USA 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: Canada 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: Canada 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • JAPAN
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Japan 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Japan 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • CHINA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: China 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: China 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • EUROPE
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: Europe 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: Europe 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Europe 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • FRANCE
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: France 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: France 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • GERMANY
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: Germany 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: Germany 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Italy 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: Italy 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: UK 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: UK 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: Spain 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: Spain 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Russia 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Russia 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Rest of Europe 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Rest of Europe 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: Australia 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: Australia 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • INDIA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 115: India 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 118: India 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 121: South Korea 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 124: South Korea 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Kidney Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 133: Latin America 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 136: Latin America 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 139: Latin America 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 142: Argentina 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 145: Argentina 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 148: Brazil 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 151: Brazil 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 154: Mexico 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 157: Mexico 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 160: Rest of Latin America 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 163: Rest of Latin America 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Kidney Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 166: Middle East 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 169: Middle East 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 172: Middle East 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 175: Iran 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 178: Iran 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 181: Israel 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 184: Israel 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 187: Saudi Arabia 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 190: Saudi Arabia 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 193: UAE 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 196: UAE 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 199: Rest of Middle East 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 202: Rest of Middle East 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
  • AFRICA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 205: Africa 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 208: Africa 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030

IV. COMPETITION